BOZEMAN, Mont., Feb. 6, 2023 /PRNewswire/ — Alercell celebrates today World Cancer Day in unveiling its Poster for World Cancer Day. World Cancer Day was born on the 4 February 2000 at the World Summit Against Cancer for the New Millennium in Paris. The Paris Charter aims to promote research, prevent cancer, improve patient services, raise awareness and mobilize the global community to make progress against cancer, and includes the adoption of World Cancer Day.
Alercell wants to go further, Alercell believe that a world without cancer is within reach, but we need to modify our overall attitude toward cancer. Today we have made tremendous progress in curing and healing cancer, but we need to go further. We need to eliminate it completely like we have done for numerous plagues before our time. It is possible and this is the mantra of Alercell: “Stop it before it starts!” It is possible.
“Although I congratulate the medical and the pharmaceutical industry for all the progress made in the past 20 years in their fight against cancer, at Alercell we want to go further in developing a more preventative approach. We want to detect the risks prior to seeing them coming to fruition. We can do it! Join us all in insisting on a more preventative approach to eliminate cancer” said Frederic Scheer, Alercell CEO in unveiling Alercell 2023 poster.
The poster is celebrating a recent test Lena Q51® that the company has introduced recently to diagnose Leukemia early.
Learn more about World Cancer Day at: https://www.worldcancerday.org/
Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell’s mission is to make a difference in the fight against cancer by providing innovative and accurate diagnostic solutions that improve patient outcomes.
The Alercell® mission is built on the foundation of “stopping it before it starts”. Our genetics-based testing is the first line of assault against cancer & leukemia and infectious diseases.
For more information, please visit: www.alercell.com and www.Lenadx.com
This press release includes statements relating to Alercell RUO LENA Q51 ® and its launch for Research Use Only. These statements and other statements regarding ALERCELL future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals, other healthcare providers and pharmaceutical companies, the success of our commercialization efforts for the Research Use Only product offering, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Tel 406 920 8787